Bolt Biotherapeutics, Inc.
BOLT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $1 | $1 | $4 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $1 | $1 | $4 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -2.4% | 37.5% | 354.7% | – |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | 100% | -681.4% | -1,176.4% | -5,904.4% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -864.2% | -943.9% | -1,547.5% | -7,269.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -820.8% | -878.6% | -1,537.8% | -7,824.7% |
| EPS Diluted | -1.65 | -1.83 | -2.3 | -2.79 |
| % Growth | 9.8% | 20.4% | 17.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |